USA |NASDAQ |USD
Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
---|---|---|---|---|
Aug 17, 2022 | Jun 2022 | $-0.75 | $-0.96 | $-0.46 |
Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
---|---|---|---|---|
Aug 17, 2022 | Jun 2022 | $0.00 | $0.00 | $500.00K |
Immunome, Inc's next earnings date is Wednesday, Aug 17, 2022 for the fiscal quarter ending Jun 2022.
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Sep 2022 | 2 | $-0.82 | $-0.98 | $-0.66 |
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 2 | $-2.96 | $-3.31 | $-2.62 |
Dec 2023 | 1 | $-3.29 | $-3.29 | $-3.29 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Sep 2022 | 1 / 0 | $-0.98 | $-0.89 | $-0.80 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Dec 2022 | 1 / 0 | $-3.31 | $-3.18 | $-3.05 |
Dec 2023 | 1 / 0 | $-4.32 | $-4.32 | $-4.32 |
Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
---|---|---|---|---|
Sep 2022 | 1 | $0.00 | $0.00 | $0.00 |
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 1 | $0.00 | $0.00 | $0.00 |
Dec 2023 | 1 | $7.80M | $7.80M | $7.80M |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Aug 17, 2022 | Jun 2022 | $-0.75 | - | - |
May 12, 2022 | Mar 2022 | $-0.69 | $-0.96 | -39.13% |
Mar 28, 2022 | Dec 2021 | $-0.81 | $-0.68 | 16.05% |
Nov 15, 2021 | Sep 2021 | $-0.50 | $-0.65 | -30.00% |
Aug 16, 2021 | Jun 2021 | $-0.39 | $-0.46 | -17.95% |
May 12, 2021 | Mar 2021 | $-0.41 | $-0.37 | 9.76% |
Mar 25, 2021 | Dec 2020 | $-0.29 | $-0.40 | -37.93% |
Oct 5, 2020 | Sep 2020 | $-0.38 | $-7.52 | -1878.95% |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Mar 28, 2022 | Dec 2021 | $-2.32 | $-2.16 | - |
Mar 25, 2021 | Dec 2020 | $-8.63 | $-7.92 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Aug 17, 2022 | Jun 2022 | $0.00 | - | - |
May 12, 2022 | Mar 2022 | $0.00 | $0.00 | - |
Mar 28, 2022 | Dec 2021 | $0.00 | $0.00 | - |
Nov 15, 2021 | Sep 2021 | $0.00 | $6.00K | - |
Aug 16, 2021 | Jun 2021 | $0.00 | $500.00K | - |
May 12, 2021 | Mar 2021 | $2.60M | $0.00 | - |
Mar 25, 2021 | Dec 2020 | $2.10M | $0.00 | - |
Oct 5, 2020 | Sep 2020 | $0.00 | $0.00 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Mar 28, 2022 | Dec 2021 | $0.00 | $0.00 | - |
Mar 25, 2021 | Dec 2020 | $2.10M | $0.00 | - |
IMNM's next earnings date is Wednesday, Aug 17, 2022 for the fiscal quarter ending Jun 30, 2022.
According to 2 analysts, the average EPS estimation for Immunome, Inc's next quarterly earnings is $-0.75, with a low EPS estimation of $-0.93, and a high estimation of $-0.57.
Over the last 1 month, EPS estimates have seen 1 upward revisions and 0 downward. The EPS 1 month trend is $-0.93, the last 2 month trend is $-0.81, and the 3 month trend is $-0.69.
Based on 1 analysts, the average revenue estimation is $0.00, with a low revenue estimation of $0.00, and a high estimation of $0.00.
Immunome, Inc's previous earnings date was May 12, 2022 for its fiscal quarter ended Mar 31, 2022.
IMNM's earnings per share (EPS) was $-0.96, missing the consensus analysts forecast of $-0.69 by -39.13%.
The EPS was lower than the previous fiscal quarter (Dec 2021) by 41.18%, and lower than the same period a year before (Mar 2021) by 159.46%.
Revenues were $0.00.
The company reported a net income of $-11.65M.Free cash flow for the quarter was $-6.38M , compared to $-6.82M last quarter and $-3.57M a year before.
IMNM ended the quarter with $208.00K in total debt.
Immunome, Inc's previous annual earnings date was Mar 28, 2022 for its fiscal year ended Dec 31, 2021.
IMNM's earnings per share (EPS) was $-2.16, beating the consensus analysts forecast of $-2.32 by -6.90% , and higher than the previous year's EPS (Dec 2020) by -72.73%.
Revenues were $0.00.
The company reported a net income of $-24.71M.
Immunome, Inc reported a free cash flow of $-18.30M for its fiscal year, compared to $-12.72M a year ago.